INCYTE CORP (1INCY.MI) Stock Price, Forecast & Analysis
BIT:1INCY • US45337C1027
1INCY.MI Key Statistics, Chart & Performance
The current stock price of 1INCY.MI is 95.3 EUR.
1INCY.MI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to 1INCY.MI.
1INCY.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to 1INCY.MI. Both the health and profitability get an excellent rating, making 1INCY.MI a very profitable company, without any liquidiy or solvency issues.
1INCY.MI Financial Highlights
Over the last trailing twelve months 1INCY.MI reported a non-GAAP Earnings per Share(EPS) of 5.53. The EPS increased by 575.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 24.69% | ||
| ROA | 18.78% | ||
| ROE | 25.55% | ||
| Debt/Equity | 0.01 |
1INCY.MI Forecast & Estimates
32 analysts have analysed 1INCY.MI and the average price target is 89.04 EUR. This implies a price decrease of -6.57% is expected in the next year compared to the current price of 95.3.
For the next year, analysts expect an EPS growth of 428.71% and a revenue growth 18.23% for 1INCY.MI
1INCY.MI Ownership
1INCY.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 27.74 | 44.705B | ||
| 1AE | ARGENX SE | 28.3 | 44.618B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.471B | ||
| ABVX | ABIVAX SA | N/A | 8.888B | ||
| 2X1 | ABIVAX SA | N/A | 8.872B | ||
| GLPG | GALAPAGOS NV | N/A | 1.891B | ||
| GXE | GALAPAGOS NV | N/A | 1.887B | ||
| IVA | INVENTIVA SA | N/A | 1.16B | ||
| 6IV | INVENTIVA SA | N/A | 1.112B | ||
| NANO | NANOBIOTIX | N/A | 1.055B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1INCY.MI
Company Profile
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,617 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Company Info
INCYTE CORP
1801 Augustine Cut-Off
Wilmington DELAWARE US
Employees: 2617
Phone: 13024986700
INCYTE CORP / 1INCY.MI FAQ
Can you describe the business of INCYTE CORP?
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,617 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
What is the stock price of INCYTE CORP today?
The current stock price of 1INCY.MI is 95.3 EUR. The price increased by 16.16% in the last trading session.
What is the dividend status of INCYTE CORP?
1INCY.MI does not pay a dividend.
How is the ChartMill rating for INCYTE CORP?
1INCY.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Where is INCYTE CORP (1INCY.MI) stock traded?
1INCY.MI stock is listed on the Euronext Milan exchange.
Can you provide the number of employees for INCYTE CORP?
INCYTE CORP (1INCY.MI) currently has 2617 employees.
What is the market capitalization of 1INCY stock?
INCYTE CORP (1INCY.MI) has a market capitalization of 18.71B EUR. This makes 1INCY.MI a Large Cap stock.